Stocktoria
4D Molecular Therapeutics, Inc. FDMT
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-11
4D Molecular Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M | $18.0M | $13.6M | $7.0M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M | -$56.7M | -$50.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M | -$71.3M | -$56.7M | -$49.3M |
| EPS (diluted) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | — | — |
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M | -$50.9M | -$36.7M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M | -$51.9M | -$39.9M |
| Cash & equivalents | $60.2M | $149.3M | $249.1M | $52.4M | $153.0M | $276.7M | $49.7M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M | $288.3M | $58.2M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M | $31.9M | $28.2M |
| Shareholders' equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M | $256.4M | -$73.0M |
Growth · year-over-year · Revenue CAGR 51.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +230194.6% | -99.8% | +562.3% | -82.7% | +32.5% | +94.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.